Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this clinical study has two objectives. The Primary Objective is to evaluate the effectiveness of microdosed GLP-1 receptor agonists in improving measures of health, quality of life, and longevity. The Secondary Objective: To assess the impact of these therapies on weight management practices and metabolic health.
Participants will be assigned to one of three groups: 1) control, 2) microdosed sublingual semaglutide, 3) microdosed subcutaneous semaglutide. At baseline and every 4 weeks thereafter, participants will be asked to complete surveys on health, wellness, mood, demographic information, and similar. Additionally, at baseline and every 12 weeks thereafter, they will be requested to complete evaluative blood work to measure CBC, CMP, and standard health biomarker panels (e.g., cholesterol, glucose, creatinine, sodium, potassium). From baseline throughout the duration of the study, participants will be given the option to share data from wearable activity and health trackers with the research team for greater accuracy in evaluating measures of activity, sleep, heart rate, and similar.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Oral Placebo | Placebo Comparator | Placebo administered in PCCA sub-magna compounding base only. |
|
| Sublingual GLP1 | Active Comparator | Semaglutide 1mg/1ml administered in PCCA sub-magna compounding base only. |
|
| Subcutaneous GLP1 | Active Comparator | Semaglutide 1mg/ml x5ml |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| GLP-1 | Drug | Sublingual GLP1 (weekly), Subcutaneous GLP1 (weekly), Sublingual Placebo (weekly) for up to 6 months. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in self-reported pain levels in participants microdosing GLP1s | Participants will complete an extensive medical questionnaire every 4 weeks over a 24-week period to monitor self-reported pain levels | 6 months |
| Concentration of complete blood cells, as a measure of immunological health, in participants microdosing GLP1s | CBC panel will be analyzed every 12 weeks over a 24-week period, reported in thousands of cells per microliter with the change from baseline reported as percent deviation and compared to normalized range of healthy individuals | 6 months |
| Concentration of basic metabolites (cholesterol, glucose, creatinine, sodium, potassium), as a measure of immunological health, in participants microdosing GLP1s | BMP panel will be analyzed every 12 weeks over a 24-week period, reported in mg/dL with the change from baseline reported as percent deviation and compared to a normalized range of healthy individuals | 6 months |
| Change in mood in participants microdosing GLP1s | Mood will be assessed every 4 weeks over a 24-week period using the SF-36 standardized questionnaire with deviation reported as percent change from baseline | 6 months |
| Change in heart rate variability in participants microdosing GLP1s | Participants will wear health devices with data monitored every 4 weeks over a 24-week period to observe change in heart rate variability, being defined as the variability of a participant's resting heart rate. Variability will be measured as an average deviation from baseline heart rate at each timepoint and reported as percent difference. | 6 months |
| Changes in sleep patterns in participants microdosing GLP1s |
| Measure | Description | Time Frame |
|---|---|---|
| Variation in concentration of metabolic health biomarkers in participants microdosing GLP1s | Changes in HbA1c levels will be assessed every 12 weeks and reported as a percent deviation from baseline | 6 months |
| Variation in concentration of metabolic health biomarkers in participants microdosing GLP1s |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| AgelessRx | Ann Arbor | Michigan | 48104 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 31680842 | Background | Grieco M, Giorgi A, Gentile MC, d'Erme M, Morano S, Maras B, Filardi T. Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases. Front Neurosci. 2019 Oct 18;13:1112. doi: 10.3389/fnins.2019.01112. eCollection 2019. | |
| 27633186 | Background | Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsboll T; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15. |
| Label | URL |
|---|---|
| Link to AgelessRx Research page. | View source |
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| ICF | No | No | Yes | Informed Consent Form | Aug 28, 2024 | Jul 18, 2025 | ICF_000.pdf |
Not provided
| ID | Term |
|---|---|
| D007249 | Inflammation |
| D000377 | Agnosia |
| ID | Term |
|---|---|
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010468 | Perceptual Disorders |
| D019954 | Neurobehavioral Manifestations |
Not provided
Not provided
| ID | Term |
|---|---|
| D052216 | Glucagon-Like Peptide 1 |
| C000591245 | semaglutide |
| ID | Term |
|---|---|
| D004763 | Glucagon-Like Peptides |
| D052336 | Proglucagon |
| D005768 | Gastrointestinal Hormones |
| D006728 | Hormones |
Not provided
Not provided
Single-Center, Prospective, Blinded, Randomised, Controlled Trial
Not provided
Not provided
Not provided
| Placebo | Drug | Sublingual Placebo (weekly) for up to 6 months |
|
Wearable health device data will be monitored over the 24-week period assessing REM vs non-REM sleep and reported as a ratio |
| 6 months |
| Change in frequency of physical activity in participants microdosing GLP1s | The change in frequency of physical activity, defined as a departure from baseline in time spent performing moderate to rigorous physical exercise, will be captured via wearable health device data and will be reported as percent difference from baseline in steps taken. | 6 months |
| Change in frequency of physical activity in participants microdosing GLP1s | The change in frequency of physical activity, defined as a departure from baseline in time spent performing moderate to rigorous physical exercise, will be captured via wearable health device data and will be reported as percent difference from baseline in calories burned. | 6 months |
Changes in LDL cholesterol levels will be assessed every 12 weeks and reported as a percent deviation from baseline |
| 6 months |
| Variation in concentration of metabolic health biomarkers in participants microdosing GLP1s | Changes in HDL cholesterol levels will be assessed every 12 weeks and reported as a percent deviation from baseline | 6 months |
| Variation in concentration of metabolic health biomarkers in participants microdosing GLP1s | Changes in triglyceride levels will be assessed every 12 weeks and reported as a percent deviation from baseline | 6 months |
| 29617641 | Background | Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018 Apr 3;27(4):740-756. doi: 10.1016/j.cmet.2018.03.001. |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D012816 | Signs and Symptoms |
| D006730 |
| Hormones, Hormone Substitutes, and Hormone Antagonists |